Hansoh Pharma (翰森制药) Post-IPO Trading Update: Fairly Valued
Hansoh Pharma's IPO was priced at the high end and started trading last Friday. In our earlier note, we argued that the company should trade at...
560 Views
Hansoh Pharma (翰森制药) IPO: Inebilizumab License-In from Viela Bio a Symbolic Deal
Just ahead of the launch of Hansoh Pharma's book building for its USD 1bn IPO, news reported today that Hansoh inked a license-in agreement with...
811 Views
China A-Shares: The 3rd Wave
This report looks at A-Share positioning among GEM, Asia-Ex Japan and Global funds. It serves to highlight the continued growth in both the size...
618 Views
Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
747 Views
Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)
Hansoh Pharma re-filed prospectus in April and is targeting a listing by summer. In our previous insight, we covered the company's major products...
812 Views